Fundraising FoxAveretx
1 known investors
Find your way into Averetx
Sign up to find every way you can get introduced to Averetx
- Your email: who you already know at Averetx, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Averetx team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Avere Therapeutics is a biotech company developing AVR-001, an oral once-weekly interleukin-23 receptor antagonist (IL-23RA) for chronic inflammatory diseases such as psoriasis, ulcerative colitis, Crohn's disease, and psoriatic arthritis. The drug is engineered for higher, more consistent drug exposure and a longer half-life to enable once-weekly pill dosing.
Investors · 1
Frequently asked questions
- What does Averetx do?
- Avere Therapeutics is a biotech company developing AVR-001, an oral once-weekly interleukin-23 receptor antagonist (IL-23RA) for chronic inflammatory diseases such as psoriasis, ulcerative colitis, Crohn's disease, and psoriatic arthritis. The drug is engineered for higher, more consistent drug exposure and a longer half-life to enable once-weekly pill dosing.
- Who are Averetx's investors?
- Averetx's investors include Wellington Management.